HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

NC 1153

a Jnk3 inhibitor; no further information available 9/2005

Also Known As:

NC-1153; NC1153

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amines: 4871
  - Mannich Bases: 78
    - NC 1153: 2
- Ketones: 2618
  - Mannich Bases: 78
    - NC 1153: 2

Experts

1.	Kirken, Robert A: 2 articles (01/2016 - 04/2010)
2.	Ross, Jeremy A: 2 articles (01/2016 - 04/2010)
3.	Martinez, G Steven: 1 article (01/2016)
4.	Bader, Julia: 1 article (04/2010)
5.	Dimmock, Jonathan: 1 article (04/2010)
6.	Nagy, Zsuzsanna S: 1 article (04/2010)
7.	Rodriguez, Georgialina: 1 article (04/2010)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2016 - "Jak3 inhibitors CP-690,550 and NC1153 showed efficacy in reducing viability of Ba/F3 cells transformed with mutant forms of Jak3, thus providing new therapeutic strategies to treat these types of cancer." 04/16/2010 - "IL-2 responsive NC1153 target genes were regulated in human JAK3 positive, but not in JAK3 negative lymphoid tumor cells. "
2.	Lymphoma (Lymphomas) 04/16/2010 - "In the current work, we report that specific inhibition of Janus tyrosine kinase (JAK3) via NC1153 induces apoptosis of certain leukemia/lymphoma cell lines. "
3.	Leukemia 04/16/2010 - "In the current work, we report that specific inhibition of Janus tyrosine kinase (JAK3) via NC1153 induces apoptosis of certain leukemia/lymphoma cell lines. "

Related Drugs and Biologics

1.	Protein-Tyrosine Kinases (Tyrosine Kinase)
2.	Interleukin-2 (IL2)
3.	tofacitinib